Pfizer CEO Albert Bourla is guilty of making “misleading” and unsubstantiated statements about covid “vaccines” for children.

 During a BBC interview that was published on Dec. 2, 2021, Bourla told the media outlet that children as young as five should take covid injections for protection against the disease, even though the United Kingdom medicine’s regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), did not approve the product for this age group until weeks later.

“I believe it’s a very good idea,” Bourla stated about five-to-11-year-olds taking his company’s injections. (Related: Bourla believes that anyone who objects to his company’s covid jabs is a “criminal” guilty of spreading “disinformation.”)

Citing education disruptions and the potential for children to develop so-called “long” covid, Bourla told the BBC that “there is no doubt in my mind about the benefits completely are in favor of doing it.” 

UK regulatory declare Bourla’s statements to be of a “strong unqualified nature”

The children’s welfare group UsForThem filed complaints about Bourla’s statements that led to a panel from the Prescription Medicines Code of Practice Authority (PMCPA) ruling that Bourla was out of line and had violated a number of rules in the Association of the British Pharmaceutical Industry (ABPI).

Pfizer appealed this ruling, resulting in an appeal board upholding five counts of breaches and three ABPI codes that require information and claims about drug products to be accurate, balanced, capable of substantiation, not raising unfounded hopes of successful treatment, and not being misleading as to the safety of the product – all things that Bourla did by making misleading statements. 

在 2021 年 12 月 2 日发表的 BBC 采访中，布尔拉告诉媒体，年仅五岁的儿童就应该注射新冠疫苗来预防这种疾病，尽管英国医药监管机构药品和保健品监管局 (MHRA) 直到几周后才批准该产品用于该年龄段。

 “我相信这是一个非常好的主意，”Bourla 在谈到 5 至 11 岁的孩子接受他公司的注射时说道。 （相关：布尔拉认为，任何反对其公司新冠疫苗注射的人都是传播“虚假信息”的“罪犯”。）

 布尔拉以教育中断和儿童患上所谓的“长期”新冠病毒的可能性为由，对英国广播公司表示，“毫无疑问，这样做的好处是完全赞成的。”

 英国监管机构宣布 Bourla 的声明具有“强烈的不合格性质”

 儿童福利组织 UsForThem 对 Bourla 的言论提出投诉，导致处方药执业规范管理局 (PMCPA) 的一个小组裁定 Bourla 行为不合规矩，并违反了英国制药工业协会 (ABPI) 的多项规定。 ）。

 辉瑞公司对该裁决提出上诉，导致上诉委员会维持五项违规罪名和三项 ABPI 准则，这些准则要求有关药品的信息和声明准确、平衡、能够证实，不会引起毫无根据的成功治疗希望，并且不会误导消费者。 产品的安全性——Bourla 通过做出误导性陈述所做的所有事情。